University of Michigan
University of Michigan
Positions and Employment
Clinical Fellow in Pathology, Harvard Medical School (2001-2004); Research Fellow, Department of Pathology, Brigham and Women’s Hospital, Boston (2003-2008); Instructor in Pathology, Harvard Medical School (2004-2008); Assistant (2008-2015) and Associate Professor with tenure (2015-), Department of Pathology, University of Michigan; Research Assistant (2008-2015 ) and Associate (2015-) Professor, Institute of Gerontology, University of Michigan; Associate Director, Cancer Biology Training Program, University of Michigan (3T32CA009676; 2017-)
Honors: Harvard College: summa cum laude, Phi Beta Kappa (1992); K08 award, NIA/NIH (2004); Hartford Center of Excellence Career Development award (2007); Scholar, Biological Sciences Scholars Program, University of Michigan (2008); Ellison Medical Foundation New Scholar in Aging (2009); American Federation for Aging Research award (2010); Elsa U. Pardee Foundation award (2010); Member, The American Society for Clinical Investigation (2016-); St. Baldrick’s Foundation award (2016); Melanoma Research Alliance Team Science award (2016); Harrington Discovery Institute Scholar-Innovator award (2017)
The focus of the Lombard laboratory is the biology of sirtuin proteins and their relationships with mammalian disease, especially cancer, focusing on melanoma. Dr. Lombard did his doctoral studies with Dr. Lenny Guarente at MIT, studying Werner syndrome and related progerias. After Pathology residency, Dr. Lombard pursued postdoctoral work in Dr. Fred Alt’s laboratory, where he studied the sirtuins SIRT3 and SIRT6, work supported by a K08 award from NIA/NIH. Dr. Lombard was the first to describe a central role for SIRT3 in regulating mitochondrial protein acetylation (cited >600 times per Google Scholar). Subsequent studies have revealed that SIRT3 is a major player in regulating metabolism, the pro-longevity calorie restriction response, in tumor suppression, and cardioprotection. He set up his independent lab at the University of Michigan in 2008. Among Dr. Lombard’s most significant recent contributions have been describing SIRT6’s tumor suppressor function via repression of tumor cell metabolism (Cell); and novel aspects of mitochondrial regulation by SIRT5 (Molecular Cell). His lab contributed to the discovery of SIRT5’s non-canonical catalytic activities. He is a member of the Aging Cell and JBC editorial boards. He was named a New Scholar in Aging of the Ellison Medical Foundation, a member of The American Society for Clinical Investigation, and a Scholar-Innovator of the Harrington Discovery Institute.Dr. Lombard past and current trainees include 3 predocs and 9 postdocs; two of the latter are now Assistant Professors at other institutions.